 |
| july
6, 2026 |
| Regional
intelligence on Drugs, Diagnostics,
Devices & Digital Health |
|
|
|
* may need subscription to view |
|
BIG4BIO
CEO WEEKLY Q&A:
CONTINUING TOMORROW! |
| Due
to the 4th of July holiday, we will have
our next CEO Q&A tomorrow with Jehee
Suh, CEO, Inocras - check out our previous
Q&As here. |
|
|
 |
| Biotech’s
most flexible vivarium lab space
to launch and scale studies. |
|
Learn More
→ |
|
|
- Agenus: Landmark BOT+BAL Data Showing 33%
Three-Year Overall Survival in Refractory MSS
Metastatic Colorectal Cancer Without Active
Liver Metastases at ESMO GI 2026 More
- Insulet: Accelerates Global Growth with
Launch of Omnipod 5 and Omnipod Discover in
Spain, Expanding Access to Tubeless Diabetes
Technology More
- PharmaEssentia:
Health Canada Approval of BESREMi
(ropeginterferon alfa-2b) for Polycythemia
Vera (PV) More
|
|
 |
Charles
River CFO
Keeping It Steady During a
Company-Defining Moment |
|
Learn More
→ |
|
|
- Akebia Therapeutics: Inducement Grants Under
Nasdaq Listing Rule 5635(c)(4) More
- Bicara Therapeutics: Inducement Grants Under
Nasdaq Listing Rule 5635(c)(4) More
- Boston’s 10 World Trade Sits Empty Amid Lab
Market Crash More*
- Dianthus Therapeutics: Inducement Grants
Under Nasdaq Listing Rule 5635(C)(4) More
- French Drugmaker Commits to Cambridge
Headquarters Years Ahead of Schedule More*
- Monte Rosa: Inducement Grants Under Nasdaq
Listing Rule 5635(c)(4) More
- More on PureTech Spinout Landing $180M
From Investors Including RA Capital, Leaps
by Bayer More*
More*
More*
- More on Takeda Making Fresh AI Drug
Discovery Bet With Insilico Medicine
More
- Praxis Precision Medicines: Inducement
Grants Under Nasdaq Listing Rule 5635(c)(4) More
- Spyre Therapeutics: Grants of Inducement
Awards More
- Thymmune Therapeutics Acquired by
Maryland Biotech for $140M More*
More*
More
More
- Verastem Oncology: Inducement Grants Under
Nasdaq Listing Rule 5635(c)(4) More
- Vor Bio: Inducement Grant Under Nasdaq
Listing Rule 5635(c)(4)
More
- Xenon Pharmaceuticals: Inducement Grants
Under Nasdaq Listing Rule 5635(c)(4) More
|
|
|
 |
Pace®
Life Sciences
The CDMO That Takes You Further.
Your partner for Product
Development, Manufacturing,
Analytical Testing, Regulatory
Consulting & Operational
Support. |
|
Learn More
→ |
|
|
- A Decade on the Map: How Big4Bio’s
Regions Moved in GEN’s Top 10 Biopharma
Clusters, 2016–2026 More
- A Year After Distressed Buyout, What’s
Become of Bluebird Bio? More*
- Dyne CEO on Establishing a Pure-Play
Neuromuscular Company More*
- More on Vertex Saying Casgevy Label
Expansion Opens Treatment to 5,500 More US
Children More
- My Seven Health Tech Observations From HLTH
Europe 2026 Event More
- Subscribe to LifeSci Startup for
Updates on US Startups More
|
|
- Corbus Pharmaceuticals: Appoints Leonardo
Viana Nicacio, M.D. as Chief Medical Officer
More
- ICYMI: A View From the Trenches - Biotech
Series A in 2026 More
- Nona Biosciences: Appoints Dr. Peng Wang
as Chief Operating Officer to Advance
Platform Capabilities and Drive Operational
Excellence More
- OPPORTUNITY: Chief Executive Officer,
Cambridge, MA
More
- OPPORTUNITY: Chief Financial Officer, Pine
Brook, NJ / Hybrid
More
- OPPORTUNITY: President, Business
Development, New England Region, Remote More
- OPPORTUNITY: Vice President, Global BD,
Remote
More
- Slone Partners: How to De-Risk
Executive Hiring Decisions in Life Sciences
and Healthcare
More
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: Boston Life Science
Company Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:Boston,
all rights reserved 2026
© 2026
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
